WaPo
The class-action lawsuit filed six years ago against drugmaker Eli Lilly alleging systematic overpricing of insulin has ended with the company agreeing to pay a $13.5 million settlement and to continue its cap on users’ out-of-pocket costs for four years.
Under the settlement, those unable to qualify for the $35-a-month cap ― people who no longer use Eli Lilly insulin or those now enrolled in the Medicare and Medicaid programs ― may tap into the $13.5 million fund, which is also being used to pay administration costs and fees for the plaintiffs’ attorneys.
Keywords